Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease

• Published in: Science translational medicine Vol. 6; no. 226; p. 226ra30
• Main Authors: Fagan, Anne M, Xiong, Chengjie, Jasielec, Mateusz S, Bateman, Randall J, Goate, Alison M, Benzinger, Tammie L S, Ghetti, Bernardino, Martins, Ralph N, Masters, Colin L, Mayeux, Richard, Ringman, John M, Rossor, Martin N, Salloway, Stephen, Schofield, Peter R, Sperling, Reisa A, Marcus, Daniel, Cairns, Nigel J, Buckles, Virginia D, Ladenson, Jack H, Morris, John C, Holtzman, David M
• Format: Journal Article
• Language: English
• Published: United States 05.03.2014
• Subjects: Adult; Alleles; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - genetics; Amyloid beta-Peptides - cerebrospinal fluid; Biomarkers - cerebrospinal fluid; Cognition; Cohort Studies; Cross-Sectional Studies; Disease Progression; Female; Genes, Dominant; Homozygote; Humans; Immunoassay; Male; Middle Aged; Mutation; Peptide Fragments - cerebrospinal fluid; Phosphorylation; Positron-Emission Tomography; Time Factors

Clinicopathological evidence suggests that the pathology of Alzheimer's disease (AD) begins many years before the appearance of cognitive symptoms. Biomarkers are required to identify affected individuals during this asymptomatic ("preclinical") stage to permit intervention with poten...